A challenging summer quarter at the level of last year

SIGNIFICANT EVENTS DURING THE THIRD QUARTER 2024 (JUL – SEP)

• Mentice and AGIK, the Working Group of Interventional Cardiology within the German Society of Cardiology (DGK), have announced a strategic three-year partnership to transform interventional cardiology training in Germany.

SIGNIFICANT EVENTS AFTER END OF PERIOD

• Mentice announced a significant order from a top 20 global Med Tech company, a long-standing customer of Mentice, of 630 000 USD
• Mentice announced a significant order from a top 20 global Med Tech company of 1 062 750 EURO.
• Mentice launched the VIST Ankyras integration, allowing for physicians to rehearse a procedure based on the results of an Ankyras simulation.

THIRD QUARTER 2024 (JUL- SEP)

• Order intake amounted to 61 (65) MSEK, a decrease of -6%.
• Net sales amounted to 58 (64) MSEK, a decrease of -10%, whereof -8% organic, 2% acquired and -4% currency effect.
• Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to -6.2 (4.0) MSEK.
• Net income for the period amounted to -13.1 (0.0) MSEK.
• Earnings per share (EPS) were -0.51 (0.00) SEK.
• Cash flow from operating activities amounted to -2.7 (42.3) MSEK.

NINE MONTHS 2024 (JUL - SEP)

• Order intake amounted to 170 (200) MSEK, a decrease of -15%.
• The order book by the end of the period was 117 (129) MSEK, a decrease of -9%.
• Net sales amounted to 204 (203) MSEK, an increase of 0%, whereof -1% organic, 1% acquired and 0% currency effect.
• Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to -0.1 (21.9) MSEK.
• Net income for the period amounted to -20.5 (0.0) MSEK.
• Earnings per share (EPS) were -0.80 (0.00) SEK.
• Cash flow from operating activities amounted to 4.5 (44.8) MSEK.

The downloadable report can be accessed on the Mentice Investor Relations website under Financial Reports and Presentations. This link provides full details on our latest financials, strategic initiatives, and market outlook.

‍

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-07 08:30 CET.